PFIZER INC Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- PFIZER INC return tang equity for the quarter ending 2026-06-28 was -28.50%, a change of 48.23% year-over-year.
- PFIZER INC return tang equity for the quarter ending 2026-03-29 was -62.82%, a change of 0.60% year-over-year.
- PFIZER INC return tang equity for the quarter ending 2025-12-31 was -48.57%, a change of 2.01% year-over-year.
- PFIZER INC return tang equity for the quarter ending 2025-09-28 was -103.26%, a change of -71.41% year-over-year.
- PFIZER INC return tang equity for fiscal 2025 was -48.57%, a change of 2.01% from fiscal 2024.
- PFIZER INC return tang equity for fiscal 2024 was -50.58%, a change of -39.19% from fiscal 2023.
- PFIZER INC return tang equity for fiscal 2023 was -11.39%, a 105.20% decline from fiscal 2022.
- PFIZER INC return tang equity for fiscal 2022 was 218.99%, a 24.88% decline from fiscal 2021.
- Available history
- 2007-12-31 to 2026-06-28
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |